Investigating the role of glutamate in glioblastoma
Role of Glutamate-mediate Excitotoxicity in Invasion and Progression Processes of Glioblastoma Multiforme
This study is testing how levels of glutamate in blood and spinal fluid might affect the growth of glioblastoma in patients suspected of having this aggressive brain tumor.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | IRCCS San Raffaele Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Milan, Milan) |
| Trial ID | NCT05775458 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on glioblastoma multiforme (GBM), the most aggressive type of primary brain tumor. It aims to analyze the levels of glutamate and its related enzymes in serum and cerebrospinal fluid (CSF) to understand their role in tumor growth and invasion. A total of 40 patients suspected of having GBM will undergo blood sampling and MRI imaging at baseline and during follow-up at 3, 6, and 9 months. The study will collect molecular biology data alongside oncological and imaging information to explore potential therapeutic targets.
Who should consider this trial
Good fit: Ideal candidates are adult patients with a brain lesion suspected to be GBM who are eligible for gross total tumor resection.
Not a fit: Patients under 18 years old, those with liver disease, severe anemia, or who are pregnant may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new therapeutic approaches targeting glutamate signaling in glioblastoma treatment.
How similar studies have performed: While the role of glutamate in glioblastoma is being explored, this specific approach of measuring glutamate levels as biomarkers is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients with a brain lesion suspected for GBM, candidate to gross total tumor resection (GTR), followed by radiotherapy and chemotherapy (concomitant and adjuvant). * Patient able to provide informed consent. Exclusion Criteria: * Age \< 18 years * Liver disease * Severe anemia (Hb \<8mg/dl) * Pregnancy
Where this trial is running
Milan, Milan
- IRCCS San Raffaele Scientific Institute — Milan, Milan, Italy (Recruiting)
Study contacts
- Study coordinator: Sincinelli Laura
- Email: sincinelli.laura@hsr.it
- Phone: 0226436658
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.